Head-to-head · Cost-Efficiency Index
Effecty vs Alan Meds
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Effecty
People who want competitive compounded pricing but also the option to step up to brand-name, verified and nationwide.
Visit EffectyAlan Meds
Budget-first shoppers who want the lowest sema price plus an oral route nationwide.
Visit Alan MedsThe verdict
Effecty takes it, leading the Cost-Efficiency Index 86 to 84. Mid-market compounded pricing plus FDA-approved brand access and LegitScript verification, nationwide — value with a safety-net formulary. Alan Meds still earns a B — Budget-first shoppers who want the lowest sema price plus an oral route nationwide.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Effecty.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Effecty | Alan Meds |
|---|---|---|
| Cost-Efficiency Index | 86/100 | 84/100 |
| Semaglutide / mo | $160/mo | $99/mo |
| Tirzepatide / mo | $240/mo | $145/mo |
| Semaglutide / yr (modeled) | $1,920 | $1,188 |
| Tirzepatide / yr (modeled) | $2,880 | $1,740 |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | Yes |
| Brand-name access | Yes | Compounded only |
| Rank here | #14 | #19 |
Effecty
86/100Where the value is
- Both molecules disclosed at competitive prices with all-50 access
- Offers FDA-approved brand-name access alongside compounded
- LegitScript-certified pharmacy
The tradeoffs
- Per-month cost is mid-market, not budget-tier
- No oral/sublingual option
Alan Meds
84/100Where the value is
- $99 semaglutide and $145 tirzepatide — among the cheapest disclosed in the ranking
- Nationwide all-50 access with an oral/sublingual option
- Both molecules published for straightforward cost modeling
The tradeoffs
- Not LegitScript-certified — oversight harder to verify
- Compounded only — no brand-name access
Regulatory note: the FDA issued a warning letter to Alan Health Technologies Inc. dba Alan in February 2026. We still list and link to Alan Meds; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.